Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

As of 2019, 62 insulin products had been removed from the market. Luckily, there are many alternative insulins, both rapid-acting and long-acting. Zilbermint highlights Lantus (insulin glargine ...

New insulin analogues such as the long-acting analogue insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without ...

Pharmaceutical giant Sanofi has capped the price of its insulin, becoming the last of ... per month price cap on Lantus for those with private insurance. Sanofi's changes follow in the footsteps ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...